70705-33-8Relevant articles and documents
Microwave-Assisted Suzuki–Miyaura and Sonogashira Coupling of 4-Chloro-2-(trifluoromethyl)pyrido[1,2-e]purine Derivatives
Tber, Zahira,Biteau, Nicolas G.,Agrofoglio, Luigi,Cros, Julien,Goffinont, Stéphane,Castaing, Bertrand,Nicolas, Cyril,Roy, Vincent
, p. 5756 - 5767 (2019/08/20)
The convenient preparation of three imidazo[1,2-a]pyridine-2-carboxamide intermediates is reported through known Strecker–Ugi type multicomponent reactions, Tschitschibabin type condensations, and further synthetic sequences. The derivatives were then efficiently converted to novel 4-chloro-2-(trifluoromethyl)pyrido[1,2-e]purines by their original reactions with 2,2,2-trifluoroacetamide, followed by subsequent dehydroxychlorination reactions. These compounds were cross-coupled under microwave irradiation through SuzukiMiyaura and Sonogashira palladium(0) catalysis to various aromatic and alkynyl reagents, thus providing the related C-4 substituted pyrido[1,2-e]purines of biological interest in good yields.
Discovery of imidazopyridine derivatives as highly potent respiratory syncytial virus fusion inhibitors
Feng, Song,Hong, Di,Wang, Baoxia,Zheng, Xiufang,Miao, Kun,Wang, Lisha,Yun, Hongying,Gao, Lu,Zhao, Shuhai,Shen, Hong C.
supporting information, p. 359 - 362 (2015/03/30)
A series of imidazolepyridine derivatives were designed and synthesized according to the established docking studies. The imidazopyridine derivatives were found to have good potency and physical-chemical properties. Several highly potent compounds such as 8ji, 8jl, and 8jm were identified with single nanomolar activities. The most potent compound 8jm showed an IC50 of 3 nM, lower microsome clearance and no CYP inhibition. The profile of 8jm appeared to be superior to BMS433771, and supported further optimization.
INDOLIZINE INHIBITORS OF 5-LIPOXYGENASE
-
Page/Page column 107, (2011/04/24)
Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of 5-lipoxygenase (5-LO). Also described herein are methods of using such 5-LO inhibitors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other leukotriene-dependent or leukotriene mediated conditions, diseases, or disorders.